Does CBIO have a going-concern flag? — Data Unavailable
CRESCENT BIOPHARMA, INC.'s going-concern status could not be determined from the SEC filings currently cached. Either no annual filing (10-K, 20-F, 40-F) has been processed yet, or the auditor's report block in the latest annual could not be parsed.
What “Going Concern” Means for CBIO Shareholders
The going-concern qualification is a specific accounting and auditing concept governed by PCAOB AS 2415 (US) and ISA 570 (international). When an independent auditor concludes that conditions or events raise substantial doubt about the company's ability to continue as a going concern for at least twelve months following the date of the financial statements, they are required to include an explanatory paragraph (pre-2017) or emphasis-of-matter paragraph (post-2017) in the audit report. For CRESCENT BIOPHARMA, INC., no such paragraph appears in the most recent audit report. That means the auditor has affirmatively concluded that there is not substantial doubt as of the audit opinion date.
We don't currently have enough cached annual-filing text to make a determination for CBIO. The page will update automatically once the most recent annual filing is processed and the auditor's report block can be parsed.
DredgeCap derives this status purely from structural extraction of the auditor's report and management's discussion-and-analysis sections in CBIO's cached SEC filings. We do not paraphrase, characterize, or apply AI interpretation to the going-concern signal — every classification on this page maps directly to the presence or absence of specific PCAOB-defined language patterns in the source filing. That discipline is deliberate: misclassifying going-concern status is a material harm to both shareholders and the company.
For broader context on CBIO's risk profile beyond going-concern, see the CBIO Overview page for DredgeCap's full filing analysis, or the Legal Proceedings page for disclosed litigation history.